Raffael Kurek
AstraZeneca (United Kingdom) · 68 works · 2,916 citations · h-index 20
Top works
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain
- Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
- Proteomics of human breast ductal carcinoma in situ.
- Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis
- Integrated functional genomics approach for the design of patient-individual antitumor vaccines.
- Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital.
- Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis
- Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis
- Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
- Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
- Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors
- Breast cancer proteomics by laser capture microdissection, sample pooling, 54‐cm IPG IEF, and differential iodine radioisotope detection
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.
- Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
- Changes of serum HER2 status during clinical course of metastatic breast cancer patients.
- Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- Erratum to: Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1